Journal
ACTA DERMATO-VENEREOLOGICA
Volume 100, Issue -, Pages 108-114Publisher
ACTA DERMATO-VENEREOLOGICA
DOI: 10.2340/00015555-3400
Keywords
bullous pemphigoid; epidermolysis bullosa acquisita; translational medical research; disease models; animal autoantibodies
Categories
Funding
- Research Training Group Modulation of Autoimmunity from the Deutsche Forschungsgemeinschaft [GRK 1727]
- Excellence Cluster Inflammation at Interfaces from the Deutsche Forschungsgemeinschaft [EXC 306]
- Excellence Cluster Precision Medicine in Chronic Inflammation from the Deutsche Forschungsgemeinschaft [EXC 2167]
- Miltenyi Biotec
- Biogen
- Biotest
- Almirall
- True North Therapeutics
- UCB Pharma
- ArgenX
- TxCell
- Topadur
- Incyte
- Admirx
Ask authors/readers for more resources
Pemphigoid diseases are organ-specific autoimmune diseases of the skin and/or mucous membranes. They are caused by autoantibodies targeting adhesion molecules located at the dermal-epidermal junction. While the diagnostics of pemphigoid diseases and insights into their pathogenesis have improved significantly, the development of novel treatments that are effective and safe remains an unmet medical need. However, numerous pre-clinical studies and early clinical trials have recently been launched. This review summarizes some pathways leading to drug development in pemphigoid diseases, namely: (i) hypothesis-driven drug development; (ii) omics-based drug development; (iii) drug repurposing; (iv) screening-based drug development; and (v) drug development based on careful clinical observations. Ultimately, it is hoped that this will lead to personalized and curative treatments.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available